Skip to content

Lactate metabolism in Intensive Care Unit (ICU) patients with severe sepsis / septic shock with normal and elevated lactate values.

Description of muscle lactate metabolism in ICU patients with severe sepsis/septic shock in a two-compartment model using stable isotopes. An experimental, descriptive, open clinical trial.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12616000792426
Acronym
2PLS
Enrollment
20
Registered
2016-06-17
Start date
2016-08-22
Completion date
2017-02-28
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Severe sepsis / septic shock are leading causes of death in ICU:s all around the world. Improvements have been made through early identification and standardization of resuscitation (through initiatives such as Surviving Sepsis Campaign and others). In the later versions of the resuscitation guidelines a bigger focus has been put on the measurements of plasma-lactate. Increased levels have been shown to correlate with worsened outcome but a normal lactate does not exclude critical condition. Even though it is used in clinical decision-making concerning potentially lifesaving treatment, the actual metabolism of lactate in sepsis is surprisingly poorly described. In this project we aim to describe the lactate metabolism (rate of appearance and rate of disappearance) in ICU patients with severe sepsis/septic shock with normal (<2mmol/L) or elevated (>3mmol/L) levels of lactate. After recruitment and informed consent subjects will receive a femoral venous catheter and infusions of labeled lactate and phenylalanine will start. After reaching steady state concentration blood samples will be drawn from arterial and femoral lines and blood flow in the femoral artery will be assessed using Doppler ultrasound. Data from patients charts will be collected and they will be followed for 28-day mortality. Through this project we will be able to describe lactate metabolism in whole body as well as in the leg. Hopefully this increased knowledge will deepen our understanding and help us to optimize the use of lactate for clinical decision making in the future.

Interventions

All patients will be given primed infusions of both D5-labelled Phenylalanine (bolus of 0.5 mg/kg and infusion of 0.5 mg/kg/h) and 13C-labelled Lactate (bolus of 1 mg/kg and infusion of 3.65 mg/kg/h) during 3 hours, when these will have reached steady state. Patients will receive a femoral venous catheter, blood samples will be collected and blood flow in the leg examined using doppler-ultrasound. Clinical data will be collected from electronic charts.

Sponsors

Karolinska Institutet
Lead SponsorUniversity

Study design

Allocation
Non-randomised trial
Primary purpose
Diagnosis

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Severe sepsis / septic shock within 72 hours of onset. Lactate <2mmol/L or >3mmol/L

Exclusion criteria

Muscle disorders, Metformin treatment within the last five days, ongoing dialysis at time of investigation, lack of informed consent.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026